The global liver biopsy market size was valued at USD 0.99 billion in 2025 and is projected to grow from USD 1.06 billion in 2026 to USD 2.04 billion by 2035, at a CAGR of 7.53% from 2026 to 2035. North America dominated the market, accounting for a revenue share of 38.0% in 2025.
The global liver biopsy market remains a vital component of liver disease diagnosis, providing definitive tissue-based evaluation for a broad range of hepatic disorders. Despite growing adoption of non-invasive diagnostic tools such as elastography and serum biomarkers, liver biopsy continues to be the gold standard for assessing liver inflammation, fibrosis, steatosis, cirrhosis, and liver tumors, particularly in complex or inconclusive cases.
The rising prevalence of chronic liver diseases—including metabolic dysfunction-associated steatotic liver disease (MASLD), chronic hepatitis B and C, alcoholic liver disease, autoimmune hepatitis, and liver cancer—is driving demand for accurate diagnostic procedures. Increasing rates of obesity, diabetes, metabolic syndrome, and viral hepatitis further support market growth by creating a greater need for precise disease staging and treatment planning.
Technological advancements have significantly improved liver biopsy procedures through ultrasound-guided and CT-guided techniques, advanced biopsy needles, and enhanced imaging guidance, resulting in greater accuracy, reduced complications, and improved patient safety. Additionally, the growing focus on personalized medicine and the expanding pipeline of therapies for liver diseases continue to reinforce the importance of histopathological evaluation in both clinical practice and drug development.
Rising investments in specialized liver care centers, improving healthcare infrastructure, and expanding access to advanced diagnostics in emerging economies are further supporting market expansion. While non-invasive technologies are increasingly used for screening and monitoring, liver biopsy remains indispensable for definitive diagnosis, disease staging, and therapeutic decision-making, ensuring sustained demand in the global market.
Artificial intelligence (AI) is revolutionizing the market by facilitating the shift towards digital pathology and precision diagnostics other than rendering tissue sampling obsolete. Furthermore, AI algorithms facilitate the automated digitization of biopsy slides, providing high-precision evaluations of histopathological parameters such as fibrosis, steatosis, and inflammation.
AI-assisted ultrasound, CT, and MRI technologies improve lesion detection, optimize biopsy needle placement, and enhance procedural safety by helping physicians avoid critical structures. In digital pathology, AI algorithms automatically evaluate biopsy samples for fibrosis, steatosis, inflammation, and tumor characteristics, improving diagnostic accuracy while reducing interpretation time.
AI also supports predictive disease management by combining biopsy findings with clinical and genomic data to assess disease progression and treatment response, enabling more personalized patient care. As AI continues to integrate with advanced imaging, digital pathology, and precision medicine, it is making liver biopsy more accurate, efficient, and data-driven.
| Report Coverage | Details |
| Market Size in 2026 | USD 1.06 Billion |
| Market Size by 2035 | USD 2.04 Billion |
| Growth Rate From 2026 to 2035 | CAGR of 7.53% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | By Type, By End User, By Indication, By Region |
| Market Analysis (Terms Used) | Value (USD Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Becton, Dickinson and Company, MDxHealth, Veran medical, Medtronic, Argon Medical Devices, Inc., Mauna Kea Technologies, Boston Scientific Corporation, Intact Medical Corp., C. R. Bard, Inc., Leica Biosystems, Cook Medical, RI.MOS., Hologic, Inc., Sterylab, INRAD Inc., Fujifilm Medical Systems, and others. |
Rising Burden of Chronic Liver Diseases Driving Demand for Histological Diagnosis
The increasing prevalence of chronic liver diseases, including MASLD, chronic hepatitis, cirrhosis, autoimmune liver disorders, and liver cancer, is a major driver of the liver biopsy market. Rising rates of obesity, diabetes, metabolic syndrome, and alcohol-related liver disease have increased the need for accurate disease staging. Liver biopsy remains the gold standard for evaluating liver tissue, enabling precise diagnosis, fibrosis assessment, and personalized treatment planning, particularly in complex clinical cases.
Availability of Non-Invasive Diagnostic Alternatives Limiting Procedure Volumes
The growing adoption of non-invasive diagnostic technologies, such as transient elastography, magnetic resonance elastography, FibroScan, and serum biomarker tests, is limiting the number of liver biopsy procedures. These methods reduce patient discomfort and procedural risks while enabling repeated disease monitoring. As a result, liver biopsy is increasingly reserved for cases requiring definitive histological confirmation, creating a challenge for market growth.
Expanding Precision Hepatology and Personalized Medicine Creating Long-Term Growth Opportunities
The shift toward precision hepatology is creating significant opportunities for the liver biopsy market. Increasing use of personalized treatment strategies, targeted therapies, molecular diagnostics, digital pathology, and AI-driven tissue analysis is enhancing the clinical value of liver biopsy. In addition, expanding clinical trials for liver diseases, growing investments in specialized liver care centers, and improving access to advanced diagnostics in emerging economies are expected to support sustained market growth.
Why did the percutaneous biopsy segment dominate the global liver biopsy market?
The percutaneous biopsy segment dominated the market with the largest share in 2025. The dominance of the segment can be attributed to the increasing incidence of chronic liver diseases and innovations in ultrasound and CT imaging guidance. In addition, a percutaneous liver biopsy is a medical procedure in which a specialized needle is advanced through the abdominal wall and into the liver for the sample collection.
How did the laparoscopic biopsy segment expected to hold the significantly growing global liver biopsy market in the coming years?
The laparoscopic biopsy segment is expected to grow at the fastest CAGR over the forecast period. The growth of the segment can be credited to the surge in demand for minimally invasive alternatives to blind percutaneous procedures and the rise in liver disorders such as cirrhosis and hepatitis. Laparoscopy enables direct visualization of the liver surface
Why did the nonalcoholic fatty liver disease segment dominate the global liver biopsy market?
The nonalcoholic fatty liver disease segment dominated the market with the largest share in 2025. The dominance of the segment can be linked to the increasing rates of type-2 diabetes and obesity along with the surge in clinical trials. NASH is increasingly the main cause of chronic liver disease, hepatocellular carcinoma (HCC), and liver transplants globally.
How did the chronic hepatitis B or C segment expected to hold the significantly growing global liver biopsy market in the coming years?
The chronic hepatitis B or C segment is expected to grow at the fastest CAGR over the forecast period. The growth of the segment can be driven by continuous monitoring needs and growing disease awareness. The growing incidence of metabolic disorders such as non-alcoholic fatty liver disease (NAFLD) is leading to segment growth further.
Why did the hospital segment dominate the global liver biopsy market?
The hospitals segment dominated the market with the largest share in 2025. The dominance of the segment is owing to comprehensive care abilities needed to manage procedural complications and cutting-edge diagnostic imaging infrastructure. Furthermore, hospitals are equipped with advanced imaging technologies, including ultrasound, CT, fluoroscopy, and MRI systems.
How did the tertiary care centers segment expected to hold the significantly growing global liver biopsy market in the coming years?
The tertiary care centers segment is expected to grow at the fastest CAGR over the forecast period. The growth of the segment is due to the presence of skilled gastroenterology teams and high procedure volumes. Tertiary hospitals possess the necessary financial resources to acquire advanced imaging equipment and establish sophisticated molecular diagnostic laboratories.
Why did the North American region account for the largest share in the global liver biopsy market?
North America dominated the market with the largest share in 2025. The dominance of the region can be attributed to the growing rates of alcohol consumption and a robust presence of major medical device manufacturers. In addition, the widespread accessibility of specialized hepatic centers, comprehensive healthcare networks, and digital electronic health record (EHR) systems enables proactive medical screening and continuous disease management.
U.S. Global Liver Biopsy Market Trends
The growth of the market in the country can be driven by favorable reimbursement policies and the growing incidence of chronic liver diseases such as MASLD and ALD. Also, the United States medical sector benefits extensively from the broad distribution of dedicated hepatic facilities and advanced diagnostic imaging methodologies.
Why did the Asia-Pacific region become the fastest-growing global liver biopsy market during the forecast period?
Asia Pacific is expected to grow at the fastest CAGR over the forecast period. The growth of the region can be credited to the growing incidence of metabolic-dysfunction-associated steatotic liver disease and growing healthcare infrastructure. Furthermore, government initiatives, such as China's "Healthy Liver 2030" program, actively promote early diagnosis, hence directly increasing overall market expansion.
China Global Liver Biopsy Market Trends
The market in the country is growing due to extensive adoption of advanced imaging and AI-assisted biopsy tools in major Tier-1 hospitals and a surge in the middle-class population. China carries the largest burden of chronic hepatitis B (HBV) globally, along with a high prevalence of hepatitis C (HCV).
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has liver biopsy market.
By Type
By End User
By Indication
By Region
Liver Biopsy Market
Download Sample
Request Customization
Request Customization
Download Sample